The state of California currently has 194 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Recruiting
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
05/16/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Compassionate Cancer Care Medical Group, Fountain Valley, California
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma